Kevin McCaffrey

Kevin McCaffrey graduated from Rutgers University. He is a reporter with MM&M.

Most Recent Articles by Kevin McCaffrey

Vertex's Orkambi nabs FDA approval but may face payer backlash

Vertex's Orkambi nabs FDA approval but may face payer backlash

The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.

Five things for pharma marketers to know: Monday, July 6

Five things for pharma marketers to know: Monday, July 6

Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company

Top 100 Agencies 2015: PulseCX

Top 100 Agencies 2015: PulseCX

Searching for transformational change

Top 100 Agencies 2015: McCann Regan Campbell Ward

Top 100 Agencies 2015: McCann Regan Campbell Ward

Being part of something bigger is okay

Top 100 Agencies 2015: Havas Life Metro

Top 100 Agencies 2015: Havas Life Metro

Efforts to diversify roster

More Articles by Kevin McCaffrey

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.